Why ISO 81060-3 Matters for Continuous Blood Pressure Devices Continuous non-invasive blood pressure monitoring is fundamentally different from intermittent cuff readings. Instead of producing a single systolic and diastolic value at discrete time points, continuous systems output frequent blood pressure estimates and trends over time. ISO 81060-3 defines the clinical validation framework for evaluating continuous non-invasive blood pressure devices under standardized condi

Planning a Blood Pressure Validation Study Designing a blood pressure validation study requires careful planning to support reliable measurement comparisons. Early clinical trial protocol development should clearly define the device’s intended use, primary accuracy endpoints, and reference method used for comparison. This up-front structure helps keep study execution, data collection, and reporting consistent from the first participant through the final report. Key Eleme

Why Multi-Site Studies Matter Physiological monitoring devices increasingly rely on clinical evidence that reflects real-world use and diverse populations. Some studies may require clinical data to be collected across multiple research locations. Multi-site clinical research studies allow sponsors to expand recruitment and collect larger datasets while maintaining consistent study protocols. When executed under Good Clinical Practice (GCP) and ISO 14155, multi-site program

Why Submission Delays Occur Regulatory submissions for physiological monitoring devices often depend on clinical evidence demonstrating device performance. When study protocols are poorly aligned with regulatory expectations, organizations may encounter FDA submission delays . Common causes include: incomplete clinical datasets inconsistent study protocols inadequate documentation The Role of Clinical Trial Protocol Development A well-structured clinical trial pro

When planning a clinical research study intended to support an FDA submission , sponsors often encounter terms such as multi-site, multi-investigator , and single-site, multiple-location . While these models may appear operationally similar, they differ in oversight structure, execution, and how evidence is evaluated by the FDA—particularly for cuffless blood pressure devices . Understanding these distinctions is essential for aligning trial design with FDA expectations and w

When developing a new medical device or wearable technology, navigating the FDA regulatory pathway can be complex and resource-intensive. One of the most effective tools available to device developers is the FDA Q-Submission (Q-Sub) process . This process allows sponsors to engage the FDA early, gain clarity on requirements, and ultimately reduce the risk of costly delays in bringing innovations to market. What is an FDA Q-Submission? An FDA Q-submission is a way for dev

For medical device innovators, the leap from prototype to regulatory submission is filled with risk. Even a well-engineered product can be rejected if the clinical validation isn’t designed for FDA, CE, or MHRA expectations. That’s why more device sponsors are turning to Parameters Lab. We don’t just execute trials; we architect them for success. 1. Protocols That Mirror Regulatory Expectations Every study we design begins with a regulatory reverse-engineering process. We